Vera Therapeutics (VERA) Other Accumulated Expenses (2020 - 2026)

Vera Therapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• Quarterly Other Accumulated Expenses rose 148.53% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 148.53% YoY) and the FY2025 annual result came in at $1.9 million, up 782.95% from the prior year.
• Other Accumulated Expenses was $3.5 million for Q1 2026 at Vera Therapeutics, up from $1.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.7 million in Q3 2025 and bottomed at $174000.0 in Q3 2022.
• A 5-year average of $1.2 million and a median of $622000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses sank 73.87% — and 2025, when it surged 782.95%.
• Vera Therapeutics' Other Accumulated Expenses stood at $295000.0 in 2022, then surged by 90.85% to $563000.0 in 2023, then slumped by 61.46% to $217000.0 in 2024, then surged by 782.95% to $1.9 million in 2025, then soared by 80.95% to $3.5 million in 2026.
• Business Quant data shows VERA's Other Accumulated Expenses at $3.5 million in Q1 2026, $1.9 million in Q4 2025, and $3.7 million in Q3 2025.